ReviewNature reviews. Gastroenterology & hepatology2014
Radiation enteropathy--pathogenesis, treatment and prevention.
Review in Nature reviews. Gastroenterology & hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 264 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
264 citing papers in PubMed, 3 syntheses or guidelines pooled it, 439 citations in OpenAlex.
- Efficacy and Safety of Endoscopic Treatment for Chronic Hemorrhagic Radiation Enteropathy: A Systematic Review and Meta-analysis.Advances in therapy · 2026Pooled it
- Pooled it
- Guideline
- Benefits of an anti-inflammatory diet compared to a low-residue diet during concurrent chemoradiation therapy for patients with locally advanced cervical cancer: a randomized clinical trial.Frontiers in nutrition · 2026Trial
- Prevention of Radiotherapy-Induced Enteropathy by Probiotics (PREP): Double-Blind Randomized Placebo-Controlled Trial.Current oncology (Toronto, Ont.) · 2024Trial
- Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B).Breast (Edinburgh, Scotland) · 2023Trial
- Upregulation of S100A8/A9 Potentiates Radiation-Induced Intestinal Injury via MAPK and NF-κB Signaling Pathways.Advances in radiation oncology · 2026Article
- A spatial and temporal transcriptomic atlas of mouse intestinal regeneration in the jejunum.Nature communications · 2026Article
- Gut Microbiota Dysbiosis MediatesImmunity, inflammation and disease · 2026Article
- Intestinal epithelial memory: from inflammatory imprinting to metabolite-shaped immune tolerance.Barrier immunity · 2026Article
- Ginsenoside Rb1 mitigates radiation-induced intestinal injury through Treg expansion and IL-10-mediated epithelial regeneration.Journal of ginseng research · 2026Article
- Drug Repurposing of Verapamil for Radiation-Induced Enteropathy: Regulation of 5-LOX, Nrf2, and Intestinal Barrier Function.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The Role and Mechanism of Berberine as a Candidate Drug for the Treatment of Radiation-Induced Intestinal Injury.Journal of cellular and molecular medicine · 2026Article
- β-Elemene Rescues Radiation-Induced Enteritis by Orchestrating a Host-Microbiome Circuit That Fuels Epigenetic DNA Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Oral of PtCuS nanoclusters mitigates acute radiation-induced intestinal injury by coordinating glutathione metabolism, macrophage repolarization, and gut microbiota.Materials today. Bio · 2026Article
- Hyperbaric Oxygen Therapy for Late Radiation-Induced Duodenal Toxicity After Stereotactic Body Radiotherapy in a Patient with Cholangiocellular Carcinoma: A Unique Case Report.Current oncology (Toronto, Ont.) · 2026Article
- Ghrelin Induces CluInternational journal of molecular sciences · 2026Article
- Amifostine alleviates ionizing radiation-induced small intestinal motility dysfunction in mice by remodeling the structure of the enteric nervous system.Histochemistry and cell biology · 2026Article
- Role of circular RNAs in regulating toxicity induced by cancer therapies.Genes & diseases · 2026Review
- The microbiota-lymphocyte protective axis (MLPA): a novel paradigm for overcoming radiation-induced lymphopenia (RIL) and potentiating the efficacy of tumor immuno-combination therapy.Cancer immunology, immunotherapy : CII · 2026Review
204 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Changes in cancer incidence and mortality have been modest during the past several decades, but the number of cancer survivors has almost tripled during the same period. With an increasing cohort of cancer survivors, efforts to prevent, diagnose and manage adverse effects of cancer therapy, in general, and those of radiation therapy specifically, have intensified. Many cancer survivors have undergone radiation therapy of tumours in the pelvis or abdomen, thus rendering the bowel at risk of injury. In fact, the current prevalence of patients who have long-term radiation-induced intestinal adverse effects exceeds that of IBD. Considerable progress towards reducing toxicity of radiation therapy has been made by the introduction of so-called dose-sculpting treatment techniques, which enable precise delivery of the radiation beam. Moreover, new insights into the underlying pathophysiology have resulted in an improved understanding of mechanisms of radiation-induced bowel toxicity and in development of new diagnostic strategies and management opportunities. This Review discusses the pathogenesis of early and delayed radiation-induced bowel toxicity, presents current management options and outlines priorities for future research. By adding insight into molecular and cellular mechanisms of related bowel disorders, gastroenterologists can substantially strengthen these efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.